JP2018111728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018111728A5 JP2018111728A5 JP2018080510A JP2018080510A JP2018111728A5 JP 2018111728 A5 JP2018111728 A5 JP 2018111728A5 JP 2018080510 A JP2018080510 A JP 2018080510A JP 2018080510 A JP2018080510 A JP 2018080510A JP 2018111728 A5 JP2018111728 A5 JP 2018111728A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- composition
- eculizumab
- administered
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002224 eculizumab Drugs 0.000 claims 9
- 108010063231 eculizumab Proteins 0.000 claims 9
- 108020004459 Small Interfering RNA Proteins 0.000 claims 8
- 239000002924 silencing RNA Substances 0.000 claims 8
- 102100012341 PIGA Human genes 0.000 claims 6
- 101700037337 PIGA Proteins 0.000 claims 6
- 230000037165 Serum Concentration Effects 0.000 claims 6
- 201000006647 atypical hemolytic-uremic syndrome Diseases 0.000 claims 6
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 6
- 210000002966 Serum Anatomy 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 2
Claims (8)
- ヒトにおける発作性夜間ヘモグロビン尿症（ＰＮＨ）または非定型溶血性尿毒症症候群（ａＨＵＳ）を処置する方法において使用するための組成物であって、前記組成物は、エクリズマブを含み、前記方法は、
（ｉ）前記ヒトにＣ５を標的とするｓｉＲＮＡを投与することによって、前記ヒトの血清中の前記Ｃ５の濃度を低下させることと、その後、
（ｉｉ）前記ヒトにエクリズマブを投与することと
を含み、ここで、血清中の低下したＣ５濃度が、前記ヒトが正常血清濃度のＣ５を有する場合に投与される投与頻度および／または投薬量よりも、より少ない頻度でおよび／またはより低い投薬量で前記ヒトにエクリズマブが投与されることを可能にする、組成物。 - ヒトにおける発作性夜間ヘモグロビン尿症（ＰＮＨ）または非定型溶血性尿毒症症候群（ａＨＵＳ）を処置する方法において使用するための組成物であって、前記組成物は、Ｃ５を標的とするｓｉＲＮＡを含み、前記方法が、
（ｉ）前記ヒトにＣ５を標的とする前記ｓｉＲＮＡを含む前記組成物を投与することによって、前記ヒトの血清中の前記Ｃ５の濃度を低下させることと、その後、
（ｉｉ）前記ヒトにエクリズマブを投与することと
を含み、ここで、血清中の低下したＣ５濃度が、前記ヒトが正常血清濃度のＣ５を有する場合に投与される投与頻度および／または投薬量よりも、より少ない頻度でおよび／またはより低い投薬量で前記ヒトにエクリズマブが投与されることを可能にする、組成物。 - Ｃ５を標的とする前記ｓｉＲＮＡが、Ｃ５の血清濃度を少なくとも１０％、少なくとも２０％または少なくとも４０％低下させる、請求項１または２に記載の組成物。
- Ｃ５を標的とする前記ｓｉＲＮＡおよび／またはエクリズマブが、前記ヒトに長期的に投与される、請求項１〜３のいずれか１項に記載の組成物。
- 前記ｓｉＲＮＡが、少なくとも週１回で、少なくとも３週間、少なくとも６週間または少なくとも６ヶ月間、前記ヒトに投与される、請求項４に記載の組成物。
- エクリズマブと前記ｓｉＲＮＡとが、異なる投薬スケジュールで前記ヒトに投与される、請求項１〜５のいずれか１項に記載の組成物。
- エクリズマブが前記ヒトに月に１回、２ヶ月に１回、または３ヶ月毎に１回投与されることを特徴とする、請求項１〜６のいずれか１項に記載の組成物。
- ヒトにおける発作性夜間ヘモグロビン尿症（ＰＮＨ）または非定型溶血性尿毒症症候群（ａＨＵＳ）を処置する方法において使用するための組成物であって、前記組成物は、エクリズマブを含み、前記ヒトが、Ｃ５を標的とし、Ｃ５の血清濃度を低下させるｓｉＲＮＡの前記ヒトへの事前投与の結果として、Ｃ５の正常血清濃度と比較して低下したＣ５の血清濃度を有する、組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361806687P | 2013-03-29 | 2013-03-29 | |
| US61/806,687 | 2013-03-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Division JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018111728A JP2018111728A (ja) | 2018-07-19 |
| JP2018111728A5 true JP2018111728A5 (ja) | 2018-12-27 |
| JP6505288B2 JP6505288B2 (ja) | 2019-04-24 |
Family
ID=50686201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Active JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| JP2018080510A Active JP6505288B2 (ja) | 2013-03-29 | 2018-04-19 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016505600A Active JP6505079B2 (ja) | 2013-03-29 | 2014-03-28 | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160051673A1 (ja) |
| EP (2) | EP3473272A1 (ja) |
| JP (2) | JP6505079B2 (ja) |
| CA (1) | CA2897334A1 (ja) |
| ES (1) | ES2768648T3 (ja) |
| WO (1) | WO2014160958A1 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法 |
| KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| AU2014244116B9 (en) | 2013-03-14 | 2020-08-13 | Alnylam Pharmaceuticals, Inc. | Complement component C5 iRNA compositions and methods of use thereof |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| KR102515796B1 (ko) | 2014-12-19 | 2023-03-30 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| US20170073399A1 (en) * | 2015-09-11 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| AU2017283470B2 (en) | 2016-06-14 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies and uses thereof |
| MX2018015030A (es) * | 2016-06-17 | 2019-04-22 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y metodos de uso. |
| US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
| WO2018075758A1 (en) | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
| WO2018075761A1 (en) * | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5a in a sample |
| KR102514175B1 (ko) * | 2017-01-31 | 2023-03-29 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| PL3612208T3 (pl) * | 2017-04-21 | 2023-07-24 | Volution Immuno Pharmaceuticals Sa | Coversin do leczenia autoimmunologicznych chorób pęcherzowych |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| EP3597222A1 (en) * | 2018-07-16 | 2020-01-22 | Easemedcontrol R & D GmbH & Co KG | Treatment and diagnosis of unresolved inflammatory diseases |
| MX2021002710A (es) * | 2018-09-06 | 2021-09-23 | Univ Pennsylvania | Anticuerpos anti-c5 humanizados y usos de los mismos. |
| US20220204602A1 (en) * | 2019-04-24 | 2022-06-30 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| WO2023064809A1 (en) * | 2021-10-12 | 2023-04-20 | Vanqua Bio, Inc. | Oligonucleotides for targeting complement c5 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US20030143204A1 (en) | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| CN100349629C (zh) | 2001-09-12 | 2007-11-21 | 贝克顿迪肯森公司 | 用于药物传送的微针为基础的笔装置和使用该装置的方法 |
| US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
| AU2003234336A1 (en) | 2002-05-03 | 2003-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in preparing sirnas |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| CN1685063B (zh) | 2002-08-12 | 2011-12-21 | 新英格兰生物实验室公司 | 与基因沉默相关的方法和组合物 |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| DK2860251T3 (en) | 2004-02-12 | 2018-06-06 | Archemix Llc | APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| MX2008011323A (es) * | 2006-03-08 | 2008-11-18 | Archemix Corp | Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares. |
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| WO2009011782A2 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
| KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JP5815403B2 (ja) | 2008-08-05 | 2015-11-17 | ノバルティス アーゲー | 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法 |
| BRPI0921237A2 (pt) | 2008-11-10 | 2015-09-22 | Alexion Pharma Inc | métodos e composições para o tratamento de distúrbios associados ao complemento |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| CN102597005A (zh) | 2009-06-23 | 2012-07-18 | 阿雷克森制药公司 | 与补体蛋白质结合的双特异性抗体 |
| KR20130009784A (ko) | 2010-03-01 | 2013-01-23 | 알렉시온 파마슈티칼스, 인코포레이티드 | 악성 위축성 구진증을 치료하는 방법 및 조성물 |
| AU2014244116B9 (en) | 2013-03-14 | 2020-08-13 | Alnylam Pharmaceuticals, Inc. | Complement component C5 iRNA compositions and methods of use thereof |
-
2014
- 2014-03-28 EP EP18211716.8A patent/EP3473272A1/en active Pending
- 2014-03-28 WO PCT/US2014/032209 patent/WO2014160958A1/en active Application Filing
- 2014-03-28 ES ES14722916T patent/ES2768648T3/es active Active
- 2014-03-28 JP JP2016505600A patent/JP6505079B2/ja active Active
- 2014-03-28 US US14/779,605 patent/US20160051673A1/en not_active Abandoned
- 2014-03-28 CA CA2897334A patent/CA2897334A1/en not_active Abandoned
- 2014-03-28 EP EP14722916.5A patent/EP2978451B1/en not_active Revoked
-
2018
- 2018-04-19 JP JP2018080510A patent/JP6505288B2/ja active Active
-
2019
- 2019-05-29 US US16/425,402 patent/US20200023060A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018111728A5 (ja) | ||
| JP2018193377A5 (ja) | ||
| HRP20200434T1 (hr) | Stabilne vodene formulacije adalimumaba | |
| JP2016513097A5 (ja) | ||
| JP2017149726A5 (ja) | ||
| JP2014111603A5 (ja) | ||
| JP2019519519A5 (ja) | ||
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| JP2012193216A5 (ja) | ||
| JP2016503398A5 (ja) | ||
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2012506448A5 (ja) | ||
| JP2013231087A5 (ja) | ||
| JP2006504795A5 (ja) | ||
| EP4218813A3 (en) | High concentration anti-c5 antibody formulations | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| JP2017502074A5 (ja) | ||
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2018521007A5 (ja) | ||
| HRP20230070T1 (hr) | Tasimelteon za liječenje smith-magenis sindroma | |
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| Alten et al. | Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches | |
| JP2020500864A5 (ja) | ||
| JP2014520892A5 (ja) |